DigitalDx Ventures
VC Fund
Menlo Park, United States
DigitalDx Ventures is a Silicon Valley Venture firm uniquely positioned to find, support, mentor and grow the outliers in digital healthcare. DDX invests in early stage companies who effectively and efficiently harness the power of artificial intelligence and big data to profoundly impact outcomes in both diagnostics and therapeutics.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 42%
- Fund size:
- $140k
- Last fund:
Last updated:
For AI agents: llms.txt
Industries DigitalDx Ventures invests in
Stages DigitalDx Ventures invests in
Countries DigitalDx Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $3.5M–$20M
Investment Focus
Industry
- Health Care 8 (67%)
- Biotechnology 7 (58%)
- Health Diagnostics 5 (42%)
- Medical 2 (17%)
- Genetics 2 (17%)
Stage
- Series A 5 (42%)
- Venture - Series Unknown 3 (25%)
- Seed 2 (17%)
- Series B 1 (8%)
- Funding Round 1 (8%)
Country
- United States 6 (50%)
- Canada 1 (8%)
- Denmark 1 (8%)
- United Kingdom 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Jasmine Kim
Entrepreneur In Residence
|
Entrepreneur In Residence | Total investments: 0 | Find email | |
L. Jasmine Kim
Entrepreneur In Residence
|
Entrepreneur In Residence | Total investments: 0 | Find email | |
Steve Goldenberg
Investor Relations & Business Development Manager
|
Investor Relations & Business Development Manager | Total investments: 0 | Find email | |
Maureen Downey
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Michele Colucci
Managing Partner
|
Managing Partner | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Biotia is a health tech company spun out of Cornell Tech leveraging next-generation sequencing and artificial intelligence for rapid and precise infectious disease discovery. Their software and laboratory technology enable clinicians and researchers to guide patient treatment and improve health outcomes. | $9M / Venture - Series Unknown / Oct 01, 2026 | ||
| NOWDiagnostics develops and manufactures diagnostic tests that utilize a single drop of blood and deliver results within minutes. The company's simple diagnostic tests empower patients and caregivers with the knowledge necessary to make intelligent healthcare choices. Its ADEXUSDx product line features a lab at your fingertip, using only asingle drop of blood to test for a variety of common conditions, illnesses, and diseases with results in a matter of minutes. By eliminating the need to send tests to off-site laboratories, NOWDiagnostics has the potential to decrease by days the waiting period to determine test results. The company is currently offering an hCG (pregnancy) test in the United States and Europe, and two cardiac (heart attack) tests and three toxicology tests in Europe.NOWDiagnostics was established in 2014 and is based in Springdale, Arkansas, United States. | $22.5M / Series B / Jul 09, 2024 | ||
| GLX Analytix is a biomedical company that develops a new technology to identify a biomarker. The company was founded in 2019 and is based in Copenhagen, Denmark. | Seed / Jun 14, 2022 | ||
| AVA Health Technologies is building a disruptive software platform that addresses challenges in pediatric care for children with acute, chronic, and rare conditions Our vision is to fill the gap in funding and focus in dedicated pediatric research and to provide a collaborative ecosystem for care that can facilitate discovery of new cures. | $7.5M / Series A / Mar 24, 2022 | ||
| Optina Diagnostics develops technology for the early detection of disease through the eye. | $20.1M / Series A / Oct 28, 2021 | ||
| NephroSant is a fast-paced diagnostic startup founded by physicians, with a team of world-class scientists, engineers and clinicians, focused on applying the founding team's years of clinical research expertise to improve global kidney health. | $16M / Series A / Mar 16, 2021 | ||
| Delphi Diagnostics provide delphi’s sensitivity to endocrine therapy. It is a gene expression interpretive algorithm that measures potential disease progression on endocrine therapy in patients with hormone receptor positive HER2 negative breast cancer. | Venture - Series Unknown / Jan 01, 2019 | ||
| AVA Health Technologies is building a disruptive software platform that addresses challenges in pediatric care for children with acute, chronic, and rare conditions Our vision is to fill the gap in funding and focus in dedicated pediatric research and to provide a collaborative ecosystem for care that can facilitate discovery of new cures. | Venture - Series Unknown / Jan 01, 2019 | ||
| AEENA Dx is developing a saliva-based platform for the detection of cancer and disease. | $3.5M / Series A / Nov 01, 2018 | ||
| Optina Diagnostics develops technology for the early detection of disease through the eye. | $3.1M / Seed / Oct 10, 2018 | ||
| See all 12 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does DigitalDx Ventures invest in?
DigitalDx Ventures invests primarily in Health Care, Biotechnology and Health Diagnostics startups, most often at Series A and Venture - Series Unknown stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does DigitalDx Ventures invest in?
DigitalDx Ventures typically joins rounds of $3.5M–$20M at Series A. These are whole funding-round sizes, not DigitalDx Ventures's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds DigitalDx Ventures took part in.
How do I contact DigitalDx Ventures?
Public channels for DigitalDx Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at DigitalDx Ventures?
The team at DigitalDx Ventures includes Jasmine Kim (Entrepreneur In Residence), L. Jasmine Kim (Entrepreneur In Residence) and Steve Goldenberg (Investor Relations & Business Development Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
